BioSyent Inc. (RX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the Q3 and YTD 2025 results presentation for BioScience, Inc. My name is Rene Gorham and I'm the President and CEO of the company. Before I dive into the presentation, I'd just like to draw your attention to our forward-looking statements disclaimer. I'm likely to make some. So let's start the presentation by taking a look at our revenue and profitability. This slide shows you Sales performance of over $12 million in the third quarter ending September 30th. This is an increase of 28% versus the year ago, signifying our highest ever quarterly sales. Our EBITDA for the quarter came in just over 3.6 million, 27% growth to the year ago. And importantly, a 30% margin to sales. And our net income after tax came in just under $2.7 million, up 16% to the year ago, with a strong NEAT margin of 22%. One thing I'd like to point out here is that the NEAT growth, a lagging EBITDA growth somewhat. Just to remind you, a year ago, we made an acquisition of Tabilia for global operations, sales to global customers. The amortization of that impacts the comparison of EBITDA to a net income after tax. So on a nine-month basis, our revenue was over $33 million, 27% growth to the year ago. This was driven across our business, so all units, Canadian pharmaceutical, international, sales to international pharmaceutical customers, and our legacy business. Our EBITDA came in just over $9.5 million. That's up 35% to the year ago with a 29% EBITDA margin. And our net income after tax was over $7 million, 24% growth to the year ago. and 21 ratio to sales so the business continues to progress these results are positive they are you know generally in line with our plan for the year maybe slightly ahead and so we're we're happy to report this type of performance on a by brand bas...